|
|
|
|
|
|
|
|
|
|
New Chemotherapy Strategy Emerges in Ovarian Cancer
"...The noteworthy results stem from Japanese Gynecologic Oncology Group (JGOG) trial 3016, which established a significant survival benefit for patients who received dose-dense weekly paclitaxel plus carboplatin versus the conventional dosing schedule for those two drugs.1..."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.